新闻BenzingaBioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55... BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55... Benzinga 2026.10.06 20:31 (GMT+0) 在Benzinga上打开 其他新闻 比尔·盖茨推动制定类似飞机、汽车和医疗行业的人工智能安全规则：“我们还没有达到应有的水平” Solana ETF 结束 14 周连买创最大周流出 交易员mk4做多NEAR浮盈已超2000万美元 SOL现货ETF上周净流出2481.09万美元 以太坊现货ETF上周净流出5.42亿美元，贝莱德ETHA净流出4.77亿美元居首 埃隆·马斯克抨击亿万富翁穆克什·安巴尼在印度的“事实上的”垄断：关于星链竞争的“荒谬虚伪与夸张”
